European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

by Beatriz Florez, Greg Markey, Mariapaola Caleno, Odoardo Maria Olimpieri, Daniela Melchiorri, Doris Johanna Hovgaard, Sinan Bardakci Sarac, Karri Penttilä, Tuomo Lapveteläinen, Jonas Bergh
Published 2019-09-01